Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-13
2005-09-13
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255050, C514S275000, C514S313000, C514S338000, C514S407000
Reexamination Certificate
active
06943181
ABSTRACT:
The invention relates to the use of substituted gamma-lactone compounds in the production of medicines for treating migraines, septic shock, neurodegenerative diseases, such as multiple sclerosis, Parkinsons, Alzheimers or Huntingtons disease, inflammations and related pain, cerebral ischaemia, diabetes, meningitis, arteriosclerosis, cancer, mycosis, or for healing wounds.
REFERENCES:
patent: 100 50 663 A 1 (2002-04-01), None
patent: WO 91/02725 (1991-03-01), None
patent: WO 01/27109 (2001-04-01), None
Chabrier, P.E., et al., “Nitric Oxide Synthases: Targets For Therapeutic Strategies In Neurological Diseases”, CMLS Cellular and Molecular Life Sciences, 55, (1999), pp. 1029-1035.
Lassen et al., “Nitric Oxide Synthase Inhibition in Migraine”, Feb. 8, 1997, Gloucester Gastroenterology Group, Gloucester, UK, pp. 401-402.
Green et al., “Nitric Oxide: From Basic Research to Clinical Applications”, Feb. 2, 1999, DDT, vol. 4, pp. 47-49.
Thomsen et al., “Nitric Oxide Theory of Migraine”, 1998, Clinical Neuroscience, pp. 28-33.
Hobbs et al., “Inhibition of Nitric Oxide Synthase as a Potential Therapeutic Target”, Annu. Rev. Pharmacol. Toxicol., 1999, pp. 191-220.
Murad, Die Entdeckung Einiger Biologischer Wirkungen Von Stickstoffmonoxid Und Seiner Rolle Fur Die Zellkommunikation (Nobel-Vortrag), Angew. Chem., 1999, pp. 1977-1989.
Ignaro, “Stickstoffmonoxid: Ein Einzigartiges Endogenes Signalmolekül In Der Gefaβbiologie (Nobel-Vortag)” Angew. Chem., 1999, pp. 2003-2013.
“Discovery of Some of the Biological Effects of Nitric Oxide and Its Role in Cell Signaling (Nobel Lecture)”, Ferid Murad, Angew. Chem. Int. Ed. 1999, 38, pp. 1857-1868.
“Nitric Oxide Synthase Inhibition In Migraine”, Lassen et al., The Lancet, 1988, vol. 349, pp. 401-402.
Hennies Hagen-Heinrich
Przewosny Michael
Sundermann Bernd
Sundermann Corinna
Dentz Bernard
Grunenthal GmbH
Perman & Green, LLP.
LandOfFree
Use of substituted gamma-lactone compounds as pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of substituted gamma-lactone compounds as pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of substituted gamma-lactone compounds as pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3404466